Meryl Colton, MD MSc retweetledi
'Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity' read in Blood Advances: ow.ly/2zfP50XS43c #bloodadvances
English
Meryl Colton, MD MSc
126 posts
Meryl Colton, MD MSc
@mcolton_2
Medicine and public health. Lover of food, coffee, and mountains. Past CMR @CUInternalMed. Hematology/oncology fellow @UCSF
Katılım Kasım 2014
570 Takip Edilen273 Takipçiler
Meryl Colton, MD MSc retweetledi
Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy astctjournal.org/article/S2666-…
@MediHumdani @mshadman
English
Meryl Colton, MD MSc retweetledi
New paper in BMJ (Research Methods & Reporting):
“Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide”
led by Pedro Lopez-Ayala & Tobias Zimmermann with @GSCollins & myself
bmj.com/content/390/bm…
English
Tough real world outcomes for bispecifics.
Ajay Major, MD, MBA@majorajay
Bispecifics in R/R LBCL @BloodPortfolio: - 245 pts, 64% epcor, 60% prior CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm ashpublications.org/blood/article/…
English
Meryl Colton, MD MSc retweetledi
#Hematology Immunological consequences of #CARTcell therapy: an analysis of infectious complications and immune reconstitution | @BloodAdvances | American Society of Hematology #lymsm ashpublications.org/bloodadvances/…
English
Meryl Colton, MD MSc retweetledi
👏 Tour de force analysis of SSQ-MM, a PRO measure focused on dexamethasone in myeloma #MMsm
100s of pts filled this out: common steroid AEs include insomnia but also prox myopathy (difficulty rising from 🪑).
⬆️ SSQ-MM strongly assoc with ⬇️ QOL. Time for #downwithdex!
Tracy King@MMKingT
Building evidence to support burden of dex @gjmccaughan @jagger_jacqui @CNRU1 et al. Thanks for invitation @Maura1Dowling @SemOncNurs @RahulBanerjeeMD @Bethfaiman @mmamynurse Development and Validation of a Patient-Reported Outcome Measure to As... sciencedirect.com/science/articl…
English
Check out Dr Seshadri and my editorial on bridging therapy before CART —Bridging the Gap: Treatment Before CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma dailynews.ascopubs.org/do/bridging-ga…
English
Meryl Colton, MD MSc retweetledi
Just out! Excited about our @JCO_ASCO manuscript published concurrently with our #ASH24 presentation.
@fredhutch #CLL
Zanubrutinib vs. BR in Patients with TN CLL/SLL: Median 5-Year Follow-Up of SEQUOIA | Journal of Clinical Oncology ascopubs.org/doi/10.1200/jc…
English
Meryl Colton, MD MSc retweetledi
Meryl Colton, MD MSc retweetledi
Next up, CD22-CAR T from @StanfordMed
3 year follow up, 37/38 prior CR19 CAR T
Durable responses in one third of patients
Higher rates of SPMs - ?impact of 2x rounds of lymphodepletion
Good to see many presenters reporting NRM
#ASH24 #lymsm #TCellRx @AshAlizadeh
English
Meryl Colton, MD MSc retweetledi
Meryl Colton, MD MSc retweetledi
Very excited to share our work led by @emilyliangmd just published in @BloodAdvances!
doi.org/10.1182/blooda…
We used the {tidymodels} framework in R to develop models (eIPM) predictive of hematotoxicity in CAR T-cell therapy recipients.
Models performed well in our independent test set with:
🎯 Calibrated predictions
🎯 High discrimination (AUROC 0.87-0.88)
🎯 Higher net benefit compared to "treat all" scenario using decision curve analysis
Predictions can be generated easily using our online Shiny app: eipm.fredhutch.org
🙏 to the @fredhutch Data Science Lab (DaSL) for their help deploying the app!
Visual abstract and 🧵below by @emilyliangmd 👇
Emily Liang@emilyliangmd
Thanks to @BloodAdvances for publishing our work to develop and validate the Early ICAHT Prediction Models (eIPMs)! The eIPMs predict the probability of severe (grade 3-4) early ICAHT per the EHA/EBMT criteria across B- and plasma cell malignancies. ashpublications.org/bloodadvances/… (1/4)
English
Meryl Colton, MD MSc retweetledi
Excited to share the stage with Drs. Nathan Fowler and Paolo Strati at the Satellite Symposium during #ASH24!Don’t miss it—sign up now to join the discussion! #LymphomaResearch @CULymphoma @CUHematology @CUAnschutz @ASH_hematology
PRIME Education@PRIME_cme
Live @ ASH 2024! | Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL | Attend In-person or Virtually #MedEd #livecredit #ASH2024 #DLBCLTreatment #FollicularLymphoma #CAR-TCellTherapy | @mana1981 | bit.ly/3YEIogm
English
Meryl Colton, MD MSc retweetledi
Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/article/…
English
Meryl Colton, MD MSc retweetledi
Meryl Colton, MD MSc retweetledi
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation ashpublications.org/blood/article/…
English
Meryl Colton, MD MSc retweetledi
Long awaited IELSG37 Trial Results: Patients with mediastinal large B-cell lymphoma who achieve Deauville scores of 1-3 on PET after immunochemotherapy have excellent outcomes and do not require consolidative radiation therapy. @JCO_ASCO
ascopubs.org/doi/full/10.12…
English
Great characterization of another long term toxicity after CAR-T for myeloma. @UCSFCancer
Rahul Banerjee, MD, FACP@RahulBanerjeeMD
1/ 🚨 Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T in myeloma #MMsm. Typically non-bloody Gr3+ diarrhea starting ~3 mo after ide-cel or cilta-cel: 36% cases fatal in our series (n=14). nature.com/articles/s4140…
English
Meryl Colton, MD MSc retweetledi
In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS
English